BOULDER, Colo.--(BUSINESS WIRE)--Aug. 21, 2006--BaroFold, Inc., a private Colorado-based biotechnology company focused on improving the production and safety of challenging protein biotherapeutics through its patented high-pressure technology, announced today the appointment of Alene A. Campbell as Chief Business Officer. Ms. Campbell has over 25 years of executive management experience in corporate development, finance and marketing in the pharmaceutical industry. Before joining BaroFold, Ms. Campbell served as Vice President of Corporate Development of Myogen, Inc., where she was responsible for several licensing and partnering agreements. Previously, Ms. Campbell served as Vice President of Corporate Development of Ribozyme Pharmaceuticals, Inc. (now SiRNA), where she also served as General Manager of Ribozyme’s genomics business unit from its inception, now a German-headquartered corporation, Atugen AG. Prior to Ribozyme, Ms. Campbell held various marketing and management positions with Chem-Trak Corporation, CytoSciences, and Hana Biologics (now Cell Genesys). She holds an MBA from the University of California, Berkeley.
